ROSUVASTATIN 10mg. IP + FENOFIBRATE 145mg. IP

A combination of two lipid-lowering medicines reduces the formation of cholesterol in the body. Decreases the risk of heart diseases and helps prevent strokes and heart attacks. Facilitates efficient management of patients with dyslipidemia. (Kathleen M Fox, 2007) A well-tolerated and effective drug that exerts a good safety profile in hypercholesterolemic patients. (Charles J Glueck, 2006) Produces marked reductions in triglycerides and LDL cholesterol in type 2 diabetes patients with elevated cholesterol and triglyceride levels. (Paul N Durrington, 2004) Lessens the risk of cardiovascular events and stabilizes atherosclerosis. (Toth, 2014) Represents a three-fold greater potency at decreasing low-density lipoprotein-cholesterol than atorvastatin. (Stephen P Adams, 2014) More efficacious in improving the lipid profile of patients with hypercholesterolemia than atorvastatin, simvastatin, and pravastatin. (Peter H Jones, 2004) More efficacious than atorvastatin in modifying lipids in patients with hypercholesterolemia and a high coronary heart disease risk. (Gregory G Schwartz, 2004) Demonstrates significantly greater reductions in triglyceride and bad cholesterol, raises the levels of good cholesterol. A valuable treatment option in type 2 diabetes patients with elevated cholesterol and triglyceride levels. (Paul N Durrington, 2004)